ADMA BIOLOGICS INC (ADMA) Stock Fundamental Analysis

NASDAQ:ADMA • US0008991046

15.59 USD
-0.69 (-4.24%)
At close: Feb 12, 2026
15.7 USD
+0.11 (+0.71%)
After Hours: 2/12/2026, 6:57:06 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

7

Overall ADMA gets a fundamental rating of 7 out of 10. We evaluated ADMA against 523 industry peers in the Biotechnology industry. ADMA is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. ADMA is growing strongly while it is still valued neutral. This is a good combination! With these ratings, ADMA could be worth investigating further for growth investing!.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • ADMA had positive earnings in the past year.
  • ADMA had a positive operating cash flow in the past year.
  • ADMA had negative earnings in 4 of the past 5 years.
  • In multiple years ADMA reported negative operating cash flow during the last 5 years.
ADMA Yearly Net Income VS EBIT VS OCF VS FCFADMA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

1.2 Ratios

  • The Return On Assets of ADMA (36.83%) is better than 98.85% of its industry peers.
  • Looking at the Return On Equity, with a value of 48.57%, ADMA belongs to the top of the industry, outperforming 98.66% of the companies in the same industry.
  • ADMA has a Return On Invested Capital of 25.76%. This is amongst the best in the industry. ADMA outperforms 98.66% of its industry peers.
Industry RankSector Rank
ROA 36.83%
ROE 48.57%
ROIC 25.76%
ROA(3y)4.32%
ROA(5y)-9.88%
ROE(3y)-2.53%
ROE(5y)-28.83%
ROIC(3y)N/A
ROIC(5y)N/A
ADMA Yearly ROA, ROE, ROICADMA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400

1.3 Margins

  • With an excellent Profit Margin value of 42.87%, ADMA belongs to the best of the industry, outperforming 98.09% of the companies in the same industry.
  • ADMA has a better Operating Margin (34.19%) than 97.32% of its industry peers.
  • ADMA's Gross Margin of 54.71% is fine compared to the rest of the industry. ADMA outperforms 76.67% of its industry peers.
  • ADMA's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 34.19%
PM (TTM) 42.87%
GM 54.71%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y226.2%
GM growth 5YN/A
ADMA Yearly Profit, Operating, Gross MarginsADMA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • ADMA has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • ADMA has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, ADMA has more shares outstanding
  • Compared to 1 year ago, ADMA has an improved debt to assets ratio.
ADMA Yearly Shares OutstandingADMA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
ADMA Yearly Total Debt VS Total AssetsADMA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

  • An Altman-Z score of 18.95 indicates that ADMA is not in any danger for bankruptcy at the moment.
  • ADMA's Altman-Z score of 18.95 is amongst the best of the industry. ADMA outperforms 88.72% of its industry peers.
  • ADMA has a debt to FCF ratio of 1.78. This is a very positive value and a sign of high solvency as it would only need 1.78 years to pay back of all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 1.78, ADMA belongs to the top of the industry, outperforming 93.69% of the companies in the same industry.
  • A Debt/Equity ratio of 0.16 indicates that ADMA is not too dependend on debt financing.
  • ADMA has a worse Debt to Equity ratio (0.16) than 64.24% of its industry peers.
  • Although ADMA does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF 1.78
Altman-Z 18.95
ROIC/WACC2.07
WACC12.46%
ADMA Yearly LT Debt VS Equity VS FCFADMA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

  • ADMA has a Current Ratio of 7.13. This indicates that ADMA is financially healthy and has no problem in meeting its short term obligations.
  • ADMA has a better Current ratio (7.13) than 70.55% of its industry peers.
  • ADMA has a Quick Ratio of 3.65. This indicates that ADMA is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 3.65, ADMA is in line with its industry, outperforming 46.46% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.13
Quick Ratio 3.65
ADMA Yearly Current Assets VS Current LiabilitesADMA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 92.86% over the past year.
  • The Revenue has grown by 27.62% in the past year. This is a very strong growth!
  • ADMA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 70.84% yearly.
EPS 1Y (TTM)92.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)27.62%
Revenue growth 3Y74.04%
Revenue growth 5Y70.84%
Sales Q2Q%12%

3.2 Future

  • The Earnings Per Share is expected to grow by 33.00% on average over the next years. This is a very strong growth
  • ADMA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 21.50% yearly.
EPS Next Y19.34%
EPS Next 2Y35.12%
EPS Next 3Y33.64%
EPS Next 5Y33%
Revenue Next Year20.85%
Revenue Next 2Y22.49%
Revenue Next 3Y22.24%
Revenue Next 5Y21.5%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ADMA Yearly Revenue VS EstimatesADMA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M 1B
ADMA Yearly EPS VS EstimatesADMA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2

More info and screens

Find the best growth stocksShow best growing peers

6

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 28.87, the valuation of ADMA can be described as expensive.
  • Based on the Price/Earnings ratio, ADMA is valued cheaper than 93.12% of the companies in the same industry.
  • ADMA is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 27.67, which is the current average of the S&P500 Index.
  • With a Price/Forward Earnings ratio of 17.08, ADMA is valued on the expensive side.
  • 93.88% of the companies in the same industry are more expensive than ADMA, based on the Price/Forward Earnings ratio.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 27.69, ADMA is valued a bit cheaper.
Industry RankSector Rank
PE 28.87
Fwd PE 17.08
ADMA Price Earnings VS Forward Price EarningsADMA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • ADMA's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. ADMA is cheaper than 93.69% of the companies in the same industry.
  • 91.40% of the companies in the same industry are more expensive than ADMA, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 91.37
EV/EBITDA 22.2
ADMA Per share dataADMA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.5 1 1.5 2

4.3 Compensation for Growth

  • ADMA's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • The decent profitability rating of ADMA may justify a higher PE ratio.
  • A more expensive valuation may be justified as ADMA's earnings are expected to grow with 33.64% in the coming years.
PEG (NY)1.49
PEG (5Y)N/A
EPS Next 2Y35.12%
EPS Next 3Y33.64%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for ADMA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ADMA BIOLOGICS INC

NASDAQ:ADMA (2/12/2026, 6:57:06 PM)

After market: 15.7 +0.11 (+0.71%)

15.59

-0.69 (-4.24%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05
Earnings (Next)03-02
Inst Owners93.5%
Inst Owner Change-3.36%
Ins Owners2.35%
Ins Owner Change-0.33%
Market Cap3.71B
Revenue(TTM)488.56M
Net Income(TTM)209.45M
Analysts82.22
Price Target26.18 (67.93%)
Short Float %8.13%
Short Ratio7.39
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-1.96%
Min EPS beat(2)-1.96%
Max EPS beat(2)-1.96%
EPS beat(4)0
Avg EPS beat(4)-10.9%
Min EPS beat(4)-31.17%
Max EPS beat(4)-1.96%
EPS beat(8)3
Avg EPS beat(8)-42.78%
EPS beat(12)6
Avg EPS beat(12)-7.71%
EPS beat(16)8
Avg EPS beat(16)-5.59%
Revenue beat(2)1
Avg Revenue beat(2)-0.85%
Min Revenue beat(2)-2.51%
Max Revenue beat(2)0.81%
Revenue beat(4)2
Avg Revenue beat(4)-0.71%
Min Revenue beat(4)-3.31%
Max Revenue beat(4)2.16%
Revenue beat(8)6
Avg Revenue beat(8)4.26%
Revenue beat(12)10
Avg Revenue beat(12)4.8%
Revenue beat(16)14
Avg Revenue beat(16)6.2%
PT rev (1m)0%
PT rev (3m)-5.81%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-0.89%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.4%
Revenue NQ rev (1m)-0.18%
Revenue NQ rev (3m)-0.21%
Revenue NY rev (1m)-0.05%
Revenue NY rev (3m)0.87%
Valuation
Industry RankSector Rank
PE 28.87
Fwd PE 17.08
P/S 7.59
P/FCF 91.37
P/OCF 57.11
P/B 8.61
P/tB 8.69
EV/EBITDA 22.2
EPS(TTM)0.54
EY3.46%
EPS(NY)0.91
Fwd EY5.86%
FCF(TTM)0.17
FCFY1.09%
OCF(TTM)0.27
OCFY1.75%
SpS2.05
BVpS1.81
TBVpS1.79
PEG (NY)1.49
PEG (5Y)N/A
Graham Number4.69
Profitability
Industry RankSector Rank
ROA 36.83%
ROE 48.57%
ROCE 32.61%
ROIC 25.76%
ROICexc 29.27%
ROICexgc 29.53%
OM 34.19%
PM (TTM) 42.87%
GM 54.71%
FCFM 8.31%
ROA(3y)4.32%
ROA(5y)-9.88%
ROE(3y)-2.53%
ROE(5y)-28.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y226.2%
GM growth 5YN/A
F-Score7
Asset Turnover0.86
Health
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF 1.78
Debt/EBITDA 0.4
Cap/Depr 304.79%
Cap/Sales 4.99%
Interest Coverage 15.23
Cash Conversion 37.13%
Profit Quality 19.39%
Current Ratio 7.13
Quick Ratio 3.65
Altman-Z 18.95
F-Score7
WACC12.46%
ROIC/WACC2.07
Cap/Depr(3y)120.67%
Cap/Depr(5y)186.15%
Cap/Sales(3y)4.32%
Cap/Sales(5y)11.97%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)92.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y19.34%
EPS Next 2Y35.12%
EPS Next 3Y33.64%
EPS Next 5Y33%
Revenue 1Y (TTM)27.62%
Revenue growth 3Y74.04%
Revenue growth 5Y70.84%
Sales Q2Q%12%
Revenue Next Year20.85%
Revenue Next 2Y22.49%
Revenue Next 3Y22.24%
Revenue Next 5Y21.5%
EBIT growth 1Y45.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year64.1%
EBIT Next 3Y45.85%
EBIT Next 5Y36.27%
FCF growth 1Y272.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y501.56%
OCF growth 3YN/A
OCF growth 5YN/A

ADMA BIOLOGICS INC / ADMA FAQ

What is the fundamental rating for ADMA stock?

ChartMill assigns a fundamental rating of 7 / 10 to ADMA.


What is the valuation status of ADMA BIOLOGICS INC (ADMA) stock?

ChartMill assigns a valuation rating of 6 / 10 to ADMA BIOLOGICS INC (ADMA). This can be considered as Fairly Valued.


How profitable is ADMA BIOLOGICS INC (ADMA) stock?

ADMA BIOLOGICS INC (ADMA) has a profitability rating of 6 / 10.


What is the financial health of ADMA BIOLOGICS INC (ADMA) stock?

The financial health rating of ADMA BIOLOGICS INC (ADMA) is 8 / 10.